Month: May 2024

VANCOUVER, British Columbia, May 22, 2024 (GLOBE NEWSWIRE) — Li-FT Power Ltd. (“LIFT” or the “Company”) (TSXV: LIFT) (OTCQX: LIFFF) (Frankfurt: WS0) is pleased to report assays from 12 drill holes completed at the Shorty, BIG East, Echo, Fi Main, & Ki pegmatites within the Yellowknife Lithium Project (“YLP”) located outside the city of Yellowknife, Northwest Territories (Figure 1). Drilling intersected significant intervals of spodumene mineralization, with the following highlights:    Highlights:YLP-0283: 35 m at 1.32% Li2O, (Shorty) YLP-0274: 11 m at 1.16% Li2O, (Ki)including: 6 m at 1.87% Li2O YLP-0263: 12 m at 0.82% Li2O, (Echo)Including: 6 m at 1.29% Li2ODiscussion of Results This news release provides results for 12 drill holes (1,918 m) from Li-FT’s 2024 winter drilling program. Holes are reported from five different...

The international rating agency Moody’s Investor Service has affirmed Šiaulių Bankas long-term deposit ratings of Baa1. The outlook on the long-term deposit ratings remains stable.  “We are pleased that one of the most influential rating agencies has affirmed Šiaulių Bankas’ historically high ratings and stable outlook. This affirmation bolsters our recent developments and demonstrates confidence in our long-term growth strategy for our investors,” states Vytautas Sinius, CEO of Šiaulių Bankas. In its statement, Moody’s noted that baseline credit assessment reflects its strong capitalisation supported by healthy earnings, and sound liquidity buffers. Moody’s is one of the most influential international credit rating agencies in assessing the ability of companies and governments to meet their debt obligations. Additional information:...

UAB “Orkela,” legal entity code 304099538, registered address at Jogailos St. 4, Vilnius, Republic of Lithuania (the Issuer), whose securities (the Bonds) are listed and admitted to trading on the Bond List of Nasdaq, also the Bonds are being publicly offered under the base prospectus approved by the Bank of Lithuania on 14 November 2023, as amended by first supplement dated 24 November 2024 (the Prospectus). As stated in the Issuer’s public announcement of 15 May 2024, the Issuer is organising a webinar on 22 May 2024 at 10:00 a.m. (meeting link) to discuss the progress of the Issuer’s real estate development project.  During the webinar, the Issuer will also discuss the circumstance that the premises of the building complex under development is intended to be designed not only for educational facility and offices,...

Novaturas Group, the leader in the Baltic tourism market, has announced its results for the first quarter of 2024. In January–March, the company generated revenues of EUR 34.5 mln. This is EUR 3.7 mln. (10%) less than in the corresponding period of 2023. The company’s EBITDA (earnings before interest, taxes, depreciation and amortisation) was EUR 316 thsnd. In January–March, Novaturas Group served a total of 35.7 thsnd. customers in the Baltic States (38 thsnd. in the corresponding period last year). The net profit of the company for January–March amounted to EUR 8 thsnd. In the same period last year, it was EUR 1.57 mln. These changes are due to complex reasons: a lower demand for Egypt and customer caution due to the military conflict in the Middle East, as well as the changed competitive environment resulting in the decline in profit...

  Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEWyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and quality Approved for treatment of cancer-related bone disease and osteoporosis respectivelyBasel, May 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has granted marketing authorization for Wyost®1 (denosumab) and Jubbonti®2 (denosumab), the first and only biosimilar versions of reference medicines Xgeva®*3 and Prolia®*4 in Europe. Wyost® is approved for the treatment of cancer-related bone disease.1 Jubbonti®...

Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1 The Roche Diagnostics Tina-quant® Lp(a) assay measures lipoprotein (a) in a person’s bloodstream, and will be made available on Roche’s installed base of over 90,000 serum work area (SWA) systems worldwide. The test has been developed in collaboration with Amgen.Basel, 22 May 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Tina-quant® lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from innovative Lp(a)-lowering therapy currently in development. Lp(a) is emerging as an important, yet under-recognised, potential risk factor for...

Hydrogen storage systemThe Hexagon Purus’ hydrogen storage system that will be used in Toyota’s heavy-duty fuel cell electric powertrain kit.Battery packThe high voltage battery pack manufactured by Hexagon Purus for Toyota’s heavy-duty fuel cell electric powertrain kitAdvanced Clean Transportation (ACT) Expo, Las Vegas, Wednesday 22 May: Hexagon Purus is pleased to announce it will be supplying components to Toyota North America (TMNA) for serial production of its heavy-duty fuel cell electric powertrain kits. Hexagon Purus will be providing a full hydrogen storage system and high voltage battery pack for the heavy-duty fuel cell electric powertrain kit1. Hexagon Purus’s collaboration with Toyota started in 2017 as Toyota began development of the fuel cell electric powertrain kits for Class 8 trucks, including...

GENT, Belgium, May 22, 2024 (GLOBE NEWSWIRE) — ArcelorMittal and partners Mitsubishi Heavy Industries, Ltd. (MHI), BHP, along with Mitsubishi Development Pty Ltd (Mitsubishi Development) have successfully started operating a pilot carbon capture unit on the blast furnace off-gas at ArcelorMittal Gent in Belgium. The pilot carbon capture unit will operate for one to two years at Gent, to test the feasibility of progress to full-scale deployment of the technology, which would be able to capture a sizeable portion of the Gent site emissions, if successful.  Engineers have been working on site since January to assemble and commission the unit. In October 2022, the four parties announced their collaboration on a multi-year trial of MHI’s carbon capture technology (Advanced KM CDR ProcessTM) at multiple carbon dioxide (CO2) emission...